180 related articles for article (PubMed ID: 33472023)
1. Designed PKC-targeting bryostatin analogs modulate innate immunity and neuroinflammation.
Abramson E; Hardman C; Shimizu AJ; Hwang S; Hester LD; Snyder SH; Wender PA; Kim PM; Kornberg MD
Cell Chem Biol; 2021 Apr; 28(4):537-545.e4. PubMed ID: 33472023
[TBL] [Abstract][Full Text] [Related]
2. TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis.
Shanmukha S; Godfrey WH; Gharibani P; Lee JJ; Guo Y; Deng X; Wender PA; Kornberg MD; Kim PM
Front Cell Neurosci; 2024; 18():1373557. PubMed ID: 38841204
[TBL] [Abstract][Full Text] [Related]
3. TPPB modulates PKC activity to attenuate neuroinflammation and ameliorate experimental multiple sclerosis.
Shanmukha S; Godfrey WH; Gharibani P; Lee JJ; Guo Y; Deng X; Wender PA; Kornberg MD; Kim PM
bioRxiv; 2024 Feb; ():. PubMed ID: 38370818
[TBL] [Abstract][Full Text] [Related]
4. Characterization of designed, synthetically accessible bryostatin analog HIV latency reversing agents.
Marsden MD; Wu X; Navab SM; Loy BA; Schrier AJ; DeChristopher BA; Shimizu AJ; Hardman CT; Ho S; Ramirez CM; Wender PA; Zack JA
Virology; 2018 Jul; 520():83-93. PubMed ID: 29800728
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of potent bryostatin analogs that modulate PKC translocation selectivity.
Wender PA; Baryza JL; Brenner SE; DeChristopher BA; Loy BA; Schrier AJ; Verma VA
Proc Natl Acad Sci U S A; 2011 Apr; 108(17):6721-6. PubMed ID: 21415363
[TBL] [Abstract][Full Text] [Related]
6. Preclinical and Clinical Studies on Bryostatins, A Class of Marine-Derived Protein Kinase C Modulators: A Mini-Review.
Raghuvanshi R; Bharate SB
Curr Top Med Chem; 2020; 20(12):1124-1135. PubMed ID: 32209043
[TBL] [Abstract][Full Text] [Related]
7. Comparative analysis of the anti-chikungunya virus activity of novel bryostatin analogs confirms the existence of a PKC-independent mechanism.
Abdelnabi R; Staveness D; Near KE; Wender PA; Delang L; Neyts J; Leyssen P
Biochem Pharmacol; 2016 Nov; 120():15-21. PubMed ID: 27664855
[TBL] [Abstract][Full Text] [Related]
8. Deletion of the C26 Methyl Substituent from the Bryostatin Analogue Merle 23 Has Negligible Impact on Its Biological Profile and Potency.
Zhao X; Kedei N; Michalowski A; Lewin NE; Keck GE; Blumberg PM
Chembiochem; 2018 May; 19(10):1049-1059. PubMed ID: 29517836
[TBL] [Abstract][Full Text] [Related]
9. A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.
Nakagawa Y; Yanagita RC; Hamada N; Murakami A; Takahashi H; Saito N; Nagai H; Irie K
J Am Chem Soc; 2009 Jun; 131(22):7573-9. PubMed ID: 19449873
[TBL] [Abstract][Full Text] [Related]
10. Function through synthesis-informed design.
Wender PA; Quiroz RV; Stevens MC
Acc Chem Res; 2015 Mar; 48(3):752-60. PubMed ID: 25742599
[TBL] [Abstract][Full Text] [Related]
11. Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro.
DeChristopher BA; Loy BA; Marsden MD; Schrier AJ; Zack JA; Wender PA
Nat Chem; 2012 Sep; 4(9):705-10. PubMed ID: 22914190
[TBL] [Abstract][Full Text] [Related]
12. PKC modulator bryostatin-1 therapeutically targets CNS innate immunity to attenuate neuroinflammation and promote remyelination.
Gharibani P; Abramson E; Shanmukha S; Smith MD; Godfrey WH; Lee JJ; Hu J; Baydyuk M; Dorion MF; Deng X; Guo Y; Hwang S; Huang JK; Calabresi PA; Kornberg MD; Kim PM
bioRxiv; 2023 Aug; ():. PubMed ID: 37693473
[TBL] [Abstract][Full Text] [Related]
13. The design, synthesis, and evaluation of C7 diversified bryostatin analogs reveals a hot spot for PKC affinity.
Wender PA; Verma VA
Org Lett; 2008 Aug; 10(15):3331-4. PubMed ID: 18588309
[TBL] [Abstract][Full Text] [Related]
14. The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.
Ruan BF; Zhu HL
Curr Med Chem; 2012; 19(16):2652-64. PubMed ID: 22506770
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of designed PKC modulators for enhanced cancer immunotherapy.
Hardman C; Ho S; Shimizu A; Luu-Nguyen Q; Sloane JL; Soliman MSA; Marsden MD; Zack JA; Wender PA
Nat Commun; 2020 Apr; 11(1):1879. PubMed ID: 32312992
[TBL] [Abstract][Full Text] [Related]
16. Toward a biorelevant structure of protein kinase C bound modulators: design, synthesis, and evaluation of labeled bryostatin analogues for analysis with rotational echo double resonance NMR spectroscopy.
Loy BA; Lesser AB; Staveness D; Billingsley KL; Cegelski L; Wender PA
J Am Chem Soc; 2015 Mar; 137(10):3678-85. PubMed ID: 25710634
[TBL] [Abstract][Full Text] [Related]
17. Computer-guided design, synthesis, and protein kinase C affinity of a new salicylate-based class of bryostatin analogs.
Wender PA; Nakagawa Y; Near KE; Staveness D
Org Lett; 2014 Oct; 16(19):5136-9. PubMed ID: 25238583
[TBL] [Abstract][Full Text] [Related]
18. Biological profile of the less lipophilic and synthetically more accessible bryostatin 7 closely resembles that of bryostatin 1.
Kedei N; Lewin NE; Géczy T; Selezneva J; Braun DC; Chen J; Herrmann MA; Heldman MR; Lim L; Mannan P; Garfield SH; Poudel YB; Cummins TJ; Rudra A; Blumberg PM; Keck GE
ACS Chem Biol; 2013 Apr; 8(4):767-77. PubMed ID: 23369356
[TBL] [Abstract][Full Text] [Related]
19. Bryostatin-1 vs. TPPB: dose-dependent APP processing and PKC-α, -δ, and -ε isoform activation in SH-SY5Y neuronal cells.
Yi P; Schrott L; Castor TP; Alexander JS
J Mol Neurosci; 2012 Sep; 48(1):234-44. PubMed ID: 22700373
[TBL] [Abstract][Full Text] [Related]
20. In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication.
Marsden MD; Loy BA; Wu X; Ramirez CM; Schrier AJ; Murray D; Shimizu A; Ryckbosch SM; Near KE; Chun TW; Wender PA; Zack JA
PLoS Pathog; 2017 Sep; 13(9):e1006575. PubMed ID: 28934369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
